Research Index
Liraglutide Research Index
PSI surfaces 50 peer-reviewed studies on Liraglutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.
Alanizi AH, Alruwythi GM, Alotaibi NH et al.
Front Pediatr·2026·Human·PubMed →
A Novel Approach to Managing "Double Diabetes" in a Pediatric Patient on Insulin Pump Therapy: An Off-Label Use of a Fixed-Ratio Insulin Degludec/Liraglutide Combination.
Almoallem B, Thalange NK
Cureus·2026·Human·PubMed →
Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.
Kerr KW, Chang AT, Sulo S et al.
Child Obes·2026·Human·PubMed →
Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review.
Pasquariello T, Secondulfo F, Roscini AR et al.
Nephron·2026·Human·PubMed →
Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.
Kassem S
Diabetes Obes Metab·2026·Human·Weight Loss·PubMed →
Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.
Santos-Pereira M, Frutuoso JF, Pereira SS et al.
Front Endocrinol (Lausanne)·2026·Human·Weight Loss·PubMed →
Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
Kitsios K, Trakatelli CM
Diabetes Technol Ther·2026·Human·PubMed →
GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.
Lee JJ, Brothers T, Kim LA et al.
Ophthalmol Retina·2026·Human·PubMed →
Trends in preoperative weight loss modalities among patients receiving body contouring surgery.
Liang J, Anderson JL, Cathey JM et al.
Surg Obes Relat Dis·2026·Human·PubMed →
Successful Reversal of Tamoxifen-Associated Weight Gain and Metabolic Dysfunction with Liraglutide in a Breast Cancer Survivor: A Case Report.
Anvarbek M, Umarov D, Khalbayeva Z et al.
Clin Med Insights Case Rep·2026·Human·PubMed →
Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study.
Gilardini L, Vincenti V, Croci M et al.
J Obes·2026·Human·Weight Loss·PubMed →
Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.
Belančić A, Klobučar S, Skroče K et al.
Medicina (Kaunas)·2026·Human·Weight Loss, Glycemic Control, Cardiovascular Risk·PubMed →
Treatment of obesity with liraglutide in bipolar disorder: a case report.
Cipolla S, Vasca G, De Francesco D et al.
Front Psychiatry·2026·Human·PubMed →
Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.
Lin CH, Hung PH, Chung MC et al.
J Prev Alzheimers Dis·2026·Human·PubMed →
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
Khan SA, Marasini A, Shrestha A et al.
Dig Dis Sci·2026·Human·PubMed →
Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants.
Vera Ponce VJ
Obes Pillars·2026·Human·PubMed →
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
Rosen CB, Gee DW
Adv Surg·2026·Human·Glycemic Control, Weight Loss·PubMed →
Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response.
Zhang L, Wu W, Lu H
J Vis Exp·2026·Human·Glycemic Control, Weight Loss, Anti-Inflammatory·PubMed →
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
Sobral MVS, Menechini RB, Marçal JBC et al.
Schizophr Res·2026·Human·PubMed →
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.
Oshman L, Runyon A, Vicenzi Bal A et al.
Obes Pillars·2026·Human·PubMed →
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.
Garg DK, Wei J
Cureus·2026·Human·PubMed →
GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.
Viquez Burboa GU, Flores Guillén MÁR
Skin Appendage Disord·2026·Human·PubMed →
Comparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients.
Rivero-Moreno Y, Zamata-Ovalle D, Fontaine-Nicola A et al.
J Laparoendosc Adv Surg Tech A·2026·Human·PubMed →
Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery.
Ouyang Y, Zhong W, Chen L et al.
Obes Surg·2026·Human·Weight Loss, Glycemic Control·PubMed →
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.
Sun Y, Li X, Xu L
Endocrine·2026·Human·Glycemic Control, Weight Loss·PubMed →
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
Frey C, Etminan M
Obstet Gynecol·2026·Human·PubMed →
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Stogios N, Agarwal SM, Maksyutynska K et al.
JAMA Psychiatry·2026·Human·Weight Loss·PubMed →
Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.
Friedman MI, Harmsen WS, Camilleri M
Obesity (Silver Spring)·2026·Human·Appetite Regulation, Weight Loss·PubMed →
HNF1B-MODY (MODY-5): a rare form of diabetes with multisystemic features-two case reports.
Carvalho T, Lavrador M, Saraiva J et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists.
Carson L, Eisner M, Launay C et al.
Skin Health Dis·2026·Animal·PubMed →
Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing.
Liu X, Lin H, Shao Y et al.
Invest Ophthalmol Vis Sci·2026·Animal·Wound Healing·PubMed →
Modulation of Endoplasmic Reticulum Stress via CEBPB: A Potential Molecular Link to Therapeutic Action in Substance Use Disorders.
Zhang C, Li H, Ho MF
CNS Neurosci Ther·2026·Animal·Neuroprotection·PubMed →
Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.
Mera-Carreiro S, Ramos-Leví A, Matía-Martín P et al.
Obes Surg·2026·Animal·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study.
Bahar F, Karayol E, Lee YC et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.
Roach KA, Khazaee M, Mohar I et al.
Regul Toxicol Pharmacol·2026·Animal·PubMed →
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.
Kopitovic I
Front Endocrinol (Lausanne)·2026·Animal·Glycemic Control·PubMed →
Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus.
Barakat HE, Ibrahim MA, AbouWarda AE et al.
BMC Pharmacol Toxicol·2026·Animal·Glycemic Control·PubMed →
Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome.
Ravić MP, Srejović IM, Andjić MM et al.
Med Sci (Basel)·2026·Animal·Metabolic Syndrome·PubMed →
Liraglutide in combination with zoledronic acid and calcium carbonate and vitamin D3 for diabetic osteoporosis: efficacy and glycometabolism impact.
Wu Z, Guo J, Liu Q et al.
Am J Transl Res·2026·Animal·PubMed →
Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.
Orandi BJ, Yan L, Levan ML et al.
Obesity (Silver Spring)·2026·Animal·PubMed →
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.
Sun H, Xin X, Yan J et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.
Josey K, Liu W, Warsavage T et al.
Am J Epidemiol·2026·Animal·PubMed →
Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.
Tu ST, Chiu CF, Chou CK et al.
Endocrinol Diabetes Metab·2026·Animal·Weight Loss·PubMed →
A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis.
Duan B, Han R
FASEB J·2026·Animal·Glycemic Control·PubMed →
Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice.
Sridhar A, Palmer ES, Craig SL et al.
Diabetologia·2026·Animal·PubMed →
Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.
Li X, Liu Y, Wang F et al.
Cardiovasc Drugs Ther·2026·Animal·PubMed →
From Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists.
Dyson S, Hoenig L, Levell NJ Professor
Clin Dermatol·2026·Animal·PubMed →
[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].
Klotz T
Zentralbl Chir·2026·Animal·PubMed →
A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan.
Chiu CF, Chou CK, Hu SW et al.
Obes Res Clin Pract·2026·Animal·PubMed →
Liraglutide Attenuates Multiorgan Oxidative, Astroglial, and Mitochondrial Stress Responses in Thioacetamide-Induced Hepatic Encephalopathy.
Bilgin Y, Sari FM, Cicek B et al.
Int J Mol Sci·2026·Animal·Liver Protection·PubMed →